Safety and efficacy of Kaffes intraductal self-expanding metal stents in the management of post-liver transplant anastomotic strictures

Table 1 Patient demographics

Demographic data of patients	Stent indwelling time
	3 months	6 months
Median age at the time of Kaffes stent insertion, yr (IQR, yr)	57 (48-64)	61 (53-69)
Gender, n (%)
Male	20 (60.6)	19 (57.6)
Female	13 (39.4)	14 (42.4)
Transplant indication, n (%)1
Hepatoma	8 (14.3)	9 (16.1)
Non-alcoholic steatohepatitis	9 (16.1)	5 (8.9)
Alcoholic cirrhosis	6 (10.7)	7 (12.5)
Hepatitis C	8 (14.3)	7 (12.5)
Hepatitis B	4 (7.1)	1 (1.8)
Autoimmune hepatitis	3 (5.4)	6 (10.7)
Cryptogenic cirrhosis	6 (10.7)	3 (5.4)
Acute liver failure	2 (3.6)	3 (5.4)
Primary biliary cirrhosis	2 (3.6)	3 (5.4)
Primary sclerosing cholangitis	2 (3.6)	3 (5.4)
Polycystic liver	2 (3.6)	3 (5.4)
Alpha 1 antitrypsin deficiency	2 (3.6)	3 (5.4)
Other	2 (3.6)	3 (5.4)
Graft size, n (%)
Complete liver graft	31 (93.9)	31 (93.9)
Partial liver graft	2 (6.1)	2 (6.1)
Biliary anastomosis anatomy, n (%)
End to end	33 (100.0)	31 (93.9)
End to side	0 (0.0)	2 (6.1)
Transplant complications, n (%)
History of rejection	19 (63.3)	12 (36.4)
History of bile leak	5 (16.7)	6 (18.2)
History of hepatic artery thrombosis	1 (3.3)	2 (6.1)
History of previous anastomotic stricture	28 (93.3)	31 (93.9)
Time between transplant and Kaffes insertion, wk (IQR, wk)	79 (33-149)	80 (18-240)

¹30 Liver transplant recipients had more than 1 indication for transplant.

IQR: Interquartile range.